What are next-generation CAR-T cell therapies?
Key insights
- Chimeric antigen receptor (CAR)-T cell therapies are a type of immunotherapy that modifies a patient’s T cells to express chimeric antigen receptors (CARs) targeting cancer-specific antigens.
- This program equips clinicians with up‑to‑date, discussion‑driven insights on emerging CAR‑T therapies for high‑risk and relapsed/refractory LBCL, with a focus on innovations that shorten manufacturing time and support timely clinical integration, in the form of breaking‑news summaries, take-away clinical aids, and a panel discussion summarising findings from major 2025 congresses, to enhance understanding of next‑generation CAR‑T developments and their clinical implications.
- The program highlights both current challenges and evolving solutions in CAR‑T therapy, including logistics, safety considerations, patient eligibility, and advances in rapid‑manufacturing platforms that aim to expand access and improve outcomes.
What are the aims of this independent medical educational program?
This program aims to provide hematologists and oncologists with the latest data and discussion-based insights on emerging CAR-T cell therapies for high-risk LBCL and R/R DLBCL that aim to reduce the time of CAR-T cell therapy delivery, generating confidence for timely integration into clinical practice on approval.
What can I expect from this independent medical educational program?
This independent medical educational program provides information on the latest data and discussion-based insights on emerging CAR-T cell therapies for high-risk LBCL and R/R DLBCL, in the form of:
- breaking news summaries and onsite videos from the EHA and ASH annual meetings
- a comprehensive infographic on the most significant CAR -T therapy developments reported in 2025 for high risk LBCL and relapsed/refractory DLBCL
- and a panel discussion on the year’s most significant breakthroughs in next generation CAR-T cell therapy for high risk R/R LBCL, drawing on landmark data from EHA 2025 and ASH 2025, led by experts Marco Davila, Gloria Iacoboni, Sairah Ahmed and Anna Sureda.
Who is Spinger Health+ IME?
Springer Health+ IME is the independent medical education subsidiary of Springer Nature. With global reach and local relevance, we deliver medical education that drives change in practice.
What is CAR-T cell therapy and how does it work?
CAR-T cell therapies are a type of immunotherapy that modifies a patient’s T cells to express chimeric antigen receptors (CARs) targeting cancer-specific antigens. The modified T cells are expanded in a lab and infused back into the patient to attack cancer cells.
Who is eligible for CAR-T cell therapy?
Patients are generally eligible for CAR‑T cell therapy if they have relapsed or refractory hematologic malignancies, and importantly, most common clinical factors including age, comorbidities, organ dysfunction, infections, or performance status, should not automatically exclude them from referral. Experts recommend that patients be referred for CAR‑T evaluation as soon as their disease becomes relapsed or refractory, ideally before beginning the next line of therapy, with supportive measures such as holding or bridging therapy used when needed to stabilize high‑volume disease. Overall, CAR‑T therapy is considered feasible for the majority of patients when managed through multidisciplinary collaboration and modern supportive care.
What are the main challenges with current ex vivo CAR-T therapies?
The main challenges with current ex vivo CAR-T therapies include:
- Complex delivery logistics
- Manufacturing time (typically ~2 weeks)
- High demand and limited capacity
- Safety concerns and lack of evidence for certain patient groups
- Patient anxiety about treatment delays
- Multiple logistical hurdles reported by healthcare professionals
What are the latest CAR-T therapies?
The latest data on CAR-T therapies was covered at the 2025 EHA and ASH meetings, and is summarised in our panel discussion: Next-generation CAR-T cell therapy platforms for high-risk LBCL and R/R DLBCL: A round-up of 2025 breakthroughs, and downloadable clinical aid: Breaking down next generation CAR-T cell therapy: 2025 A year in review.
Are CD19-targeted CAR-T therapies safe long-term?
CD19-targeted CAR-T therapies are associated with minimal long-term toxicities despite prolonged remissions in B-cell malignancies.
How accessible is CAR‑T therapy?
CAR‑T therapy is highly effective but its accessibility remains limited by complex delivery logistics, safety concerns, and typical manufacturing time of two weeks, creating delays for patients with rapidly progressing disease. Emerging rapid‑manufacturing platforms like T‑Charge and FasTCAR‑T, which can produce CAR‑T cells in under two days, show promise for improving availability and reducing time‑to‑treatment in the near future.
